

Evoq Technologies Launches Twilight™: A Breakthrough, FDA-Registered Class I Medical Device

HENDERSON, NV, UNITED STATES,
November 24, 2025 /

EINPresswire.com/ -- Evoq Technologies (evoqtechnologies.com) today announced a major milestone for eye care, confirming that its innovative diagnostic device, Twilight™, is officially registered and listed with the U.S. Food and Drug Administration (FDA) as a Class I medical device and is now available for sale in the United States.



The launch of Twilight™ represents a significant advancement not only for Evoq Technologies but for the entire field of eye care. Twilight is capable of detecting dysfunction caused by not just AMD, but also diabetic eye and inherited retinal diseases.

“

Twilight™ fundamentally changes the diagnostic standard of care by revealing visual dysfunction years earlier, when timely intervention can truly make a difference in patient outcomes.”

Daniel Lindgren, CEO and founder of Evoq Technologies.

For the first time, eye care professionals can perform a fast, technician-led dark adaptation test in any clinical setting—including exam rooms, pre-test areas, or satellite clinics. The device eliminates the need for specialized dark rooms, pupil dilation, or complex logistical changes, ensuring no disruption to existing clinic workflow.

Twilight™ is engineered to enable earlier disease detection, significantly strengthen patient engagement, and

modernize the diagnostic standard of care for conditions linked to impaired dark adaptation. Note: CPT 92284 is reimbursable and straightforward, for patients who qualify.

About Evoq Technologies

Evoq Technologies is a medical device company dedicated to developing innovative, non-invasive diagnostic solutions that enhance the detection and management of ocular diseases. By focusing on early identification of functional dysfunction, Evoq aims to improve the quality of life

for patients and streamline clinical operations for eye care professionals.

Daniel Lindgren
Evoq Technologies
+1 816-529-5712

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)



Daniel Lindgren with Twilight Dark Adaptometer

This press release can be viewed online at: <https://www.einpresswire.com/article/868800902>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.